Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s

A recent study has found that Eli Lilly’s new obesity pill, known as Tirzepatide, may be as effective as injectable GLP-1s in helping individuals lose weight.

Researchers conducted a trial involving over 1,200 participants who were either given Tirzepatide or an injectable GLP-1 for 72 weeks.

The results showed that those who took Tirzepatide lost an average of 20% of their body weight, which was comparable to the weight loss seen in the group receiving the injectable GLP-1.

Tirzepatide works by targeting the same pathway as GLP-1, which helps regulate blood sugar levels and appetite.

This new pill could be a game-changer for individuals struggling with obesity, as it offers a convenient and potentially effective alternative to injectable medications.

Further research is needed to confirm these findings and evaluate the long-term safety and efficacy of Tirzepatide.

Overall, this study provides promising results that suggest Eli Lilly’s obesity pill may be a viable option for those looking to lose weight and improve their overall health.

Consult with a healthcare provider to discuss if Tirzepatide may be a suitable treatment option for you.